Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q2 2024 · 10-Q
Revenue$40.44M$40.44M+10.7% vs Q2 2023 Net Income-$1.65M-$1.65MN/M vs Q2 2023 EPS Diluted$0.00$0.00— vs Q2 2023 Gross Profit$16,909,000+3.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,185,000+149.8% Free Cash Flowderived-$1,783,000N/M Margins · derivedGross margin41.8%−3.0 pt vs Q2 2023
Operating margin2.4%−7.3 pt vs Q2 2023
Net margin-4.1%−1.5 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end